DIRS.INFO The most relevant business & tech news

☆ Here are Tuesday's biggest analyst calls: Apple, Amazon, Nike, Monster, AMD, Carvana, CVS & more
▼ + stars: | 2022-11-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are Tuesday's biggest calls on Wall Street: Bank of America reinstates Deckers as buy Bank of America called Deckers a "rare, consistent compounder." Deutsche Bank reiterates Amazon as buy Deutsche said "macro challenges are no doubt pressuring ad budgets" for Amazon, but the company continues to be well positioned. JPMorgan upgrades Carvana to neutral from underweight JPMorgan said in its upgrade of the stock that risks are now better understood. JPMorgan upgrades Monster to outperform from neutral JPMorgan said the beverage giant has an "attractive narrative." Bank of America reiterates Advanced Micro Devices as buy Bank of America said shares of AMD are attractive heading into earnings Tuesday afternoon.

☆ JPMorgan upgrades Monster Beverage, says it's attractive heading into 2023
▼ + stars: | 2022-11-01 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

JPMorgan thinks it's time to buy shares of Monster Beverage . Analyst Andrea Teixeira upgraded shares of Monster Beverage to overweight from neutral ahead of the company's third-quarter earnings results this week. "We think MNST is well positioned into 2023E from both organic top-line (JPMe: 11%) and bottom-line perspectives (JPMe: +31%)," Teixeira wrote in a Tuesday note. Several challenges remain for Monster Beverage, including rising inflation and greater competition from new entrants in the field. Shares of Monster Beverage are down just 2.4% this year.

☆ Morgan Stanley upgrades Discover Financial Services as company hopes to restart buyback program
▼ + stars: | 2022-10-26 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +3 min

Student loan growth strength The firm also expects stronger student loan growth, which also contributes to lifting its price target. In addition, Morgan Stanley sees personal loan growth accelerating to about 7% on the year in 2023 from about 4% in 2022. Discover also noted that they expect consumer payment rates to continue to normalize, adding "some tailwind to loan growth," Graseck wrote. Some offsets Graseck noted a few things that are set to offset earnings growth for the financial services company, including its reserve ratio. "We are holding DFS' reserve ratio flat over the next several years based on our outlook for rising credit losses," she said.

☆ Here are Tuesday's biggest analyst calls of the day: Apple, Amazon, Tesla, Microsoft, Rivian & more
▼ + stars: | 2022-10-25 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: Piper Sandler initiates Deckers as overweight Piper said it's bullish on the company's Hoka shoe brand. Bernstein reiterates Tesla as underperform Bernstein said it's concerned about China competition for Tesla. Mizuho reiterates Rivian as buy Mizuho said Rivian is best positioned with China concerns and potential EV slowdowns globally. Morgan Stanley reiterates Tesla as overweight Morgan Stanley lowered its price target on Tesla to $330 per share from $350 and said it's changing estimates to account for "unexpected headwinds." JPMorgan reiterates Apple as outperform JPMorgan said it has "resilient expectations" heading into Apple earnings later this week.

☆ Buy Qualcomm as chipmaker is ready for a post-smartphone world, HSBC says
▼ + stars: | 2022-10-24 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It's time to buy shares of Qualcomm as they can soar more than 50% from here, according to HSBC. Analyst Frank Lee initiated coverage of Qualcomm with a buy rating, saying it's among the best positioned semiconductor companies to deal with slowing chip demand for smartphones. "Qualcomm is best known for making chips used in smartphones, a market that is now slowing," Lee wrote in a Monday note. Qualcomm is among the U.S. companies with "limited exposure" to those restrictions, the analyst said. The analyst set a $180 price target on Qualcomm, which is roughly 55.5% upside from Friday's close at $115.74 per share.

☆ Investors should swap these 39 big portfolio losers for more promising counterparts to cut their tax bills and position themselves for bigger profits, Wall Street firm Evercore says
▼ + stars: | 2022-10-23 | by ( Marley Jay | ) www.businessinsider.com time to read: +3 min

As the year ends, investors will start to incorporate tax loss harvesting into their strategies. Selling some stocks at a loss can allow investors to defer taxes on more successful positions. Julian Emanuel at Evercore explains what to sell at a loss, and what to swap in for 2023. The stock and bond markets have given investors headaches this year, but as 2022 comes to a close, at least their losses can give investors a tax break. Below are the stocks Evercore thinks investors should use as tax loss targets, and those they think investors should swap them out for.

☆ Too cheap? 18 stocks with single-digit P/Es that are expected to rally
▼ + stars: | 2022-10-20 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

This year's relentless market sell-off may have made some stocks way too cheap, based on certain metrics. Still, there are some parts of the market where the selling may be overdone, creating buying opportunities in stocks that could rally going forward. The stock is trading at a forward price-to-earnings ratio of 6.5, and analyst expect Ford earning's to grow by 24.5% this year. The stock is trading at a forward price-to-earnings ratio of 7.9, and analysts see upside of more than 27% on average. This shows the earnings potential of Pfizer beyond the loss of exclusivity of key drugs through the end of the decade.

☆ These beaten up U.S.-listed Chinese stocks are reading at attractive levels, Evercore ISI says
▼ + stars: | 2022-10-18 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +2 min

There may be an opportunity for investors to boost performance by snapping up shares of U.S.-listed Chinese stocks trading at a relative discount to their pandemic highs, according to Evercore ISI. "Despite the obvious challenges, we view risk/reward as attractive," analysts led by Julian Emanuel wrote in a Sunday note. "China US ADRs that have fallen significantly from their Pandemic Peak but have had favorable 2023e EPS revisions — could outperform." Evercore ISI screened for US-listed Chinese American depository receipts, or ADRs, with a market capitalization about $1 billion and that are down more from their pandemic peaks than Hong Kong's Hang Seng Index, which has fallen 47% this year. Evercore also sees a steep skew of expensive downside puts versus upside calls in the iShares China Large Cap ETF (FXI).

☆ Analysts are standing by these stocks with 'robust upside' ahead of Q3 earnings
▼ + stars: | 2022-10-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Earnings season is underway and Wall Street analysts are picking their favorite stocks to buy ahead of third quarter results. In addition, "capital allocation optionality provides sources of earnings upside," according to the firm. We could see EPS of ~$1 by 2030, and view the stock as undervalued given the growth and earnings potential. This shows the earnings potential of Pfizer beyond the loss of exclusivity of key drugs through the end of the decade. ... .Capital allocation optionality provides sources of earnings upside."

☆ Here are Wednesday's biggest analyst calls of the day: AMC, Apple, Boeing, Amazon, Lyft, BJ's & more
▼ + stars: | 2022-10-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

UBS upgrades Norwegian to buy from hold UBS said it sees improved bookings for the cruise operator. Citi reiterates Apple as buy Citi said investor concerns about the company's upcoming earnings report later this month are overblown. " Credit Suisse initiates Boeing as underperform Credit Suisse said it's concerned Boeing has lost access to the China market. Bank of America reiterates Amazon as buy Bank of America said it still sees significant room for margin expansion for Amazon. Bank of America reiterates PayPal as buy Bank of America said PayPal is still a top pick and investors should buy the dip.

☆ Here are Thursday's biggest analyst calls: Apple, Exxon, Coinbase, Alphabet, Amazon, Marvell & more
▼ + stars: | 2022-09-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: Wells Fargo initiates Coinbase as underweight Wells said in its initiation of the crypto company that it sees too many headwinds for shares of Coinbase. Cowen initiates CyberArk as outperform Cowen said it sees "growth and profitability" for the company. Stifel reiterates Marvell as buy Stifel said Marvell is one of the resilient stocks in the firm's coverage. Rosenblatt upgrades Apple to buy from neutral Rosenblatt said that its survey checks show consumers love the latest iPhone products. "We upgrade Apple to Buy from Neutral, and move our price target up $29 to $189.

☆ Susquehanna downgrades PayPal to neutral, citing growing margin pressure at Braintree subsidiary
▼ + stars: | 2022-09-20 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Growth in payments subsidiary Braintree is hurting PayPal, according to Susquehanna. Analyst James Friedman downgraded the stock to neutral from positive, and lowered his price target, saying Braintree's higher transaction expenses and lower gross yields will create yield and margin pressure for PayPal in 2023 and 2024. "Braintree is quickly gaining share within PYPL's TPV, creating negative leverage from mix," Friedman wrote in a Tuesday note, referring to total payment volume. "Braintree's lower net transaction yield and gaining volume share explain much of the decline in PYPL's overall net transaction yields, and imply more stable yields within PayPal Core," the note says. Shares of PayPal cratered this year as traders pivoted away from fintech stocks amid growing inflation and recession concerns.

☆ Humana could be top retail Medicare Advantage prescription drug plan, Morgan Stanley says in upgrade
▼ + stars: | 2022-09-20 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It's time to buy Humana , which could be the top retail Medicare Advantage prescription drug plan, according to Morgan Stanley. Analyst Michael Ha upgraded the stock to overweight from equal weight, saying Humana's improved competitive position will drive earnings growth for the company. "Based on our proprietary analysis of Medicare Advantage (MA) benefit richness, we believe Humana's 2023 plan value increases are not only the highest in recent history but also positions the company as the #1 Ranked Retail Medicare Advantage prescription drug (MA-PD) plan in benefit richness amongst peers (vs. #5 ranking in the previous four years)," Ha added. Shares of Humana outperformed the broader market this year, up 8%, but the analyst expects that the health insurance company's improved offerings will drive membership growth next year. The analyst raised his price target on Humana to $549 up from $494, implying that shares can advance roughly 9.6% from Monday's closing price of $501.07.

☆ Here are Tuesday's biggest analyst calls: Amazon, Ford, Humana, Tesla, Nike, Norwegian & more
▼ + stars: | 2022-09-20 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Tuesday's biggest calls on Wall Street: Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it sees competition rising in China and that Tesla is going through a "peak China dependency" phase. Morgan Stanley upgrades Humana to overweight from equal weight Morgan Stanley said in its upgrade of the health insurer that it sees "accelerated growth." Morgan Stanley reiterates Ford as equal weight Morgan Stanley kept its equal weight rating on the automaker, but said it investors might want to buy the stock on weakness. Morgan Stanley reiterates Amazon as overweight Morgan Stanley said that its checks show that Amazon is becoming a formidable competitor to Shopify. Barclays downgrades Nike to equal weight from overweight Barclays said in its downgrade of Nike that it sees rising inventory risks.

☆ Evercore ISI downgrades Block to underperform and slashes price target, citing growing headwinds in payments
▼ + stars: | 2022-09-14 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +2 min

Increased competition Competition in the payments space is heating up and could be a headwind for Block. In addition, given expectations for a U.S. economic slowdown, Evercore ISI now sees Block's profit growth rate continuing to decline from the second half of this year through 2024. "While cross-selling Afterpay within Seller and Cash App should help, these headwinds should sustain through 2023E," Togut said. "2022E-2024E, we forecast Afterpay's gross profit growth rate will average 13%, down from 83% and 72% in 2020 and 2021, respectively." Cash App is a different story, as Evercore ISI sees it growing gross profit in the coming quarters by utilizing new products and cross-selling.

Search resuls for: "2023E"

15 mentions found